Sylvester Comprehensive Cancer Center

A new study published in JCI Insight identifies IL1RAP as an important driver of pancreatic cancer resistance and a promising therapeutic target.

For patients who do not respond as well to treatment, there are now new therapeutic options available, including innovative medications and highly promising clinical trials.

Sylvester Comprehensive Cancer Center researchers traced how IDH-mutant gliomas evolve after treatment.

Researchers used artificial intelligence methods, such as machine learning and patient-reported measures in the electronic health record, to identify a higher risk of unplanned health care use and symptom burden.

Sylvester Comprehensive Cancer Center provided hands-on training to local providers from across the Florida Keys to strengthen their ability to identify and respond to suspicious skin lesions earlier.

Sylvester Comprehensive Cancer Center researchers received a $2.7 million grant to study stress management in breast cancer survivorship.

Derek had his prostate cancer treatment at UHealth SoLé Mia where Sylvester brings its most innovative therapies and state-of-the-art technology to patients.

New research points to DNA methylation as a key factor in predicting who may respond to treatment and a potential new way to target resistant tumors.

Sylvester is launching a 12-week lifestyle medicine program to support safe weight loss for cancer survivors.

A $114,000 grant is funding a self-guided, web-based survivorship program for people with HPV‑related head and neck cancer.